Thomas A Hughes
Overview
Explore the profile of Thomas A Hughes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1529
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction: Revealing nuclear receptor hub modules from Basal-like breast cancer expression networks
Hsu S, Hui E, Liu M, Wu D, Hughes T, Smith J
PLoS One
. 2024 Nov;
19(11):e0314424.
PMID: 39561175
[This corrects the article DOI: 10.1371/journal.pone.0252901.].
2.
Al Amri W, Al Amri A, Al Abri A, Hughes T, Al Lawati F
Oncologist
. 2024 Aug;
29(12):e1714-e1722.
PMID: 39187384
Background: High prevalence of early-onset breast cancer (EOBC) has been reported in Middle Eastern populations. For example, in Oman more than 50% of patients with breast cancer (BC) are under...
3.
Khaled Y, Khot M, Aiyappa-Maudsley R, Maisey T, Pramanik A, Tiernan J, et al.
Nanoscale
. 2024 Mar;
16(14):7185-7199.
PMID: 38506227
Theranostic nanoparticles hold promise for simultaneous imaging and therapy in colorectal cancer. Carcinoembryonic antigen can be used as a target for these nanoparticles because it is overexpressed in most colorectal...
4.
Aiyappa-Maudsley R, McLoughlin L, Hughes T
Int J Mol Sci
. 2023 Sep;
24(17).
PMID: 37685898
Breast cancer is the most common cancer worldwide and a leading cause of cancer-related deaths in women. The clinical management of breast cancer is further complicated by the heterogeneous nature...
5.
Yang Q, Kelkar A, Sriram A, Hombu R, Hughes T, Neelamegham S
Sci Adv
. 2022 Sep;
8(38):eabq8678.
PMID: 36149962
Functional and epidemiological data suggest that -linked glycans on the SARS-CoV-2 Spike protein may contribute to viral infectivity. To investigate this, we created a panel of N-to-Q mutations at -glycosylation...
6.
Pramanik A, Xu Z, Ingram N, Coletta P, Millner P, Tyler A, et al.
Mol Pharm
. 2022 Aug;
19(12):4601-4611.
PMID: 35938983
Delivery of chemotherapy drugs specifically to cancer cells raises local drug doses in tumors and therefore kills more cancer cells while reducing side effects in other tissues, thereby improving oncological...
7.
Pramanik A, Xu Z, Shamsuddin S, Khaled Y, Ingram N, Maisey T, et al.
ACS Appl Mater Interfaces
. 2022 Feb;
14(9):11078-11091.
PMID: 35196008
Nanomedicines, while having been approved for cancer therapy, present many challenges such as low stability, rapid clearance, and nonspecificity leading to off-target toxicity. Cubosomes are porous lyotropic liquid crystalline nanoparticles...
8.
Baxter D, Allinson L, Al Amri W, Poulter J, Pramanik A, Thorne J, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885090
Background: poor prognosis primary breast cancers are typically treated with cytotoxic chemotherapy. However, recurrences remain relatively common even after this aggressive therapy. Comparison of matched tumours pre- and post-chemotherapy can...
9.
Armstrong G, Khot M, Portal C, West N, Perry S, Maisey T, et al.
Surg Oncol
. 2021 Nov;
40:101679.
PMID: 34839199
Background: The c-Met protein is overexpressed in many gastrointestinal cancers. We explored EMI-137, a novel c-Met targeting fluorescent probe, for application in fluorescence-guided colon surgery, in HT-29 colorectal cancer (CRC)...
10.
Lianto P, Hutchinson S, Moore J, Hughes T, Thorne J
iScience
. 2021 Nov;
24(10):103212.
PMID: 34755086
Activity of liver x receptor (LXR), the homeostatic regulator of cholesterol metabolism, is elevated in triple-negative breast cancer (BCa) relative to other BCa subtypes, driving drug resistance and metastatic gene...